Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism

by NASDAQ Market News November 18, 2021

NASDAQ Market News
Click here to email author

RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

Ads